News from isis pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 04, 2015, 09:00 ET
Isis Pharmaceuticals, Inc.

Isis Reports Financial Results And Highlights For Second Quarter 2015

 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported net income of $35.6 million and $18.9 million for the three and six months ended June...

Aug 03, 2015, 17:00 ET
Isis Pharmaceuticals, Inc.

Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia

Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the FOCUS FH phase 3 study of KYNAMRO® (mipomersen sodium) in patients with...

Aug 03, 2015, 02:00 ET
Isis Pharmaceuticals, Inc.

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense...

Jul 29, 2015, 17:06 ET
Akcea Therapeutics

Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary,...

Jul 28, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Tuesday, August 4 at 11:30 a.m. Eastern Time to...

Jul 27, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today encouraging preliminary results from an investigator-sponsored study in patients...

Jul 22, 2015, 19:17 ET
Akcea Therapeutics

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in RNA-targeted therapeutics, and Akcea Therapeutics announced today that The Lancet...

Jul 21, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that it has initiated a Phase 1/2a clinical study of ISIS-HTTRx in patients with...

Jul 14, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.15 million milestone payment from Biogen related to...

Jul 06, 2015, 07:00 ET
Akcea Therapeutics

Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), announced today that the U.S. Food and Drug...

Jun 30, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:   Corporate presentation at its 2015 Annual...

Jun 29, 2015, 14:41 ET
Isis Pharmaceuticals, Inc.

ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has been added to the Russell 1000 Index, effective June 26, 2015. The...

Jun 22, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on children with spinal muscular atrophy (SMA) who have completed the...

Jun 16, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general...

Jun 11, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants...

Jun 10, 2015, 17:30 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Thursday, June 11 at 8:30 a.m. Eastern Time to...

Jun 05, 2015, 07:00 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals' License Agreement with Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize...

Jun 04, 2015, 18:11 ET
Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

May 28, 2015, 16:00 ET
Isis Pharmaceuticals, Inc.

Webcast Alert: Akcea Therapeutics Conference Call

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Akcea Therapeutics Webcast When: Thursday,...

May 05, 2015, 10:00 ET
Isis Pharmaceuticals, Inc

Isis Reports Financial Results and Highlights for First Quarter 2015

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015...